Biotech Values

[eawolfie]

Teva Pharmaceutical (NASDAQ:TEVA), the largest generic drug maker in the world, was climbing 1.02% to $48.51, trading 2.5% above calculated support at $48.51, following comments from Oppenheimer. The firm believes the recent weakness in shares of Teva presents a long-term buying opportunity, as it continues to view 2011 as a back-half loaded year. In their view, detailed data read-out from the Phase III ALLEGRO study of Liquinimod could provide a modestly positive clinical catalyst in April, with potential approval of its version of generic Lovenox providing a positive regulatory/commercial catalyst around the middle of the year-2011. Oppenheimer maintained its target price at $65 per share.

http://www.tradershuddle.com/20110323189542/Stocks/stock-futures-fluctuate-on-global-woes-stocks-to-watch-amzn-aapl-armh-bac-gis-jbl-teva-tm.html